TriSalus Life Sciences, Inc. (NASDAQ:TLSI – Get Free Report) Director Gary Gordon bought 10,000 shares of the stock in a transaction dated Friday, May 15th. The stock was purchased at an average price of $2.46 per share, with a total value of $24,600.00. Following the purchase, the director owned 72,510 shares in the company, valued at $178,374.60. This trade represents a 16.00% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.
TriSalus Life Sciences Stock Up 13.1%
Shares of TLSI traded up $0.35 on Monday, reaching $3.03. The stock had a trading volume of 774,431 shares, compared to its average volume of 276,402. The firm has a market capitalization of $185.77 million, a price-to-earnings ratio of -2.15 and a beta of 0.56. The company has a debt-to-equity ratio of 2.58, a quick ratio of 5.46 and a current ratio of 5.78. The company has a 50-day simple moving average of $4.18 and a 200-day simple moving average of $5.13. TriSalus Life Sciences, Inc. has a 12-month low of $2.20 and a 12-month high of $7.95.
TriSalus Life Sciences (NASDAQ:TLSI – Get Free Report) last released its earnings results on Thursday, March 5th. The company reported ($0.12) EPS for the quarter, beating analysts’ consensus estimates of ($0.13) by $0.01. The firm had revenue of $13.21 million during the quarter, compared to analysts’ expectations of $13.20 million. Sell-side analysts predict that TriSalus Life Sciences, Inc. will post -0.45 EPS for the current year.
Institutional Inflows and Outflows
Wall Street Analysts Forecast Growth
A number of research analysts have recently commented on TLSI shares. Lake Street Capital lowered their target price on TriSalus Life Sciences from $10.00 to $8.00 and set a “buy” rating for the company in a research note on Wednesday, May 13th. Weiss Ratings cut TriSalus Life Sciences from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Wednesday. Wall Street Zen upgraded TriSalus Life Sciences from a “sell” rating to a “hold” rating in a research note on Saturday, March 7th. Finally, Canaccord Genuity Group lowered their price objective on TriSalus Life Sciences from $12.00 to $7.00 and set a “buy” rating for the company in a research note on Friday, March 6th. Two investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, TriSalus Life Sciences currently has an average rating of “Hold” and a consensus price target of $7.50.
Get Our Latest Analysis on TriSalus Life Sciences
About TriSalus Life Sciences
TriSalus Life Sciences, Inc is a clinical-stage biotechnology company focused on the development and commercialization of non-invasive drug–device combination therapies for oncology applications. Leveraging proprietary electroporation and ultrasound platforms, the company aims to enhance the localized delivery and efficacy of established chemotherapeutic agents while reducing systemic toxicity. Its lead programs target hard-to-treat head and neck cancers, where improved tumor control and patient tolerability remain significant unmet needs.
The company’s pipeline comprises investigational product candidates in early and mid-stage clinical trials, including studies that combine its electrochemotherapy platform with radiation therapy and immuno-oncology agents.
Featured Stories
- Five stocks we like better than TriSalus Life Sciences
- Why Applied Optoelectronics Stock May Be Near a Turning Point
- From High-Yield to High-Growth: 3 Stocks Boosting Dividends
- Is Everspin Technologies the Next AI Edge Breakout?
- 5 Robotics Stocks to Watch as Physical AI Builds Momentum
Receive News & Ratings for TriSalus Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TriSalus Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
